Wednesday, July 8, 2026

biotech · Alzheimer Disease · Major Depressive Disorder · CGTX

Cognition Therapeutics

Cognition Therapeutics is a biotech organization headquartered in Purchase, USA. It trades on NYSE under ticker CGTX. Primary therapeutic focus areas include Alzheimer Disease, Major Depressive Disorder, Primary biliary

2500 Westchester Ave, Purchase, New York 10577, US HQ
2007 Founded
32 Employees
Public company Type
CGTX · NYSE Ticker
Company details
Status
Public
HQ
2500 Westchester Ave, Purchase, New York 10577, US
Founded
2007
Employees
32
Programs
33
Drugs
26
Patents
12
Clinical program

Memory Flexibility Training

Phase 2 · other · Major Depressive Disorder

Memory Flexibility Training for Major Depressive Disorder is a Phase 2 program (other) at COGNITION THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).

Internal code Mrccbu

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
COGNITION THERAPEUTICS INC
Phase
Phase 2
Modality
other
Indication
Major Depressive Disorder
Status
completed
Trials
1

Clinical trials